$30.11
2.11% yesterday
Nasdaq, Apr 03, 10:01 pm CET
ISIN
US8688731004
Symbol
SRDX

Surmodics Inc Stock price

$30.11
-0.84 2.71% 1M
-8.09 21.18% 6M
-9.49 23.96% YTD
+3.15 11.68% 1Y
-13.70 31.27% 3Y
-1.69 5.31% 5Y
+3.90 14.88% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.65 2.11%
ISIN
US8688731004
Symbol
SRDX
Sector

Key metrics

Market capitalization $430.45m
Enterprise Value $433.33m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.45
P/S ratio (TTM) P/S ratio 3.43
P/B ratio (TTM) P/B ratio 3.85
Revenue growth (TTM) Revenue growth -9.23%
Revenue (TTM) Revenue $125.45m
EBIT (operating result TTM) EBIT $-1.75m
Free Cash Flow (TTM) Free Cash Flow $-1.93m
Cash position $30.15m
EPS (TTM) EPS $-1.02
P/E forward negative
P/S forward 3.27
EV/Sales forward 3.29
Short interest 2.21%
Show more

Is Surmodics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Surmodics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Surmodics Inc forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Surmodics Inc forecast:

Buy
33%
Hold
67%

Financial data from Surmodics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
125 125
9% 9%
100%
- Direct Costs 35 35
10% 10%
28%
90 90
15% 15%
72%
- Selling and Administrative Expenses 45 45
8% 8%
36%
- Research and Development Expense 39 39
9% 9%
31%
6.70 6.70
69% 69%
5%
- Depreciation and Amortization 8.44 8.44
10% 10%
7%
EBIT (Operating Income) EBIT -1.75 -1.75
114% 114%
-1%
Net Profit -14 -14
361% 361%
-11%

In millions USD.

Don't miss a Thing! We will send you all news about Surmodics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Surmodics Inc Stock News

Neutral
Business Wire
one day ago
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the commercial release of the Pounce™ XL Thrombectomy System, the latest in a suite of Pounce Thrombectomy systems that provide rapid endovascular removal of acute or chronic clot from peripheral arteries. In...
Neutral
Business Wire
28 days ago
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today provided the following statement in response to the U.S. Federal Trade Commission's (“FTC” or the “Agency”) announcement that it will challenge the proposed acquisition of Surmodics (the “Merger”) by funds affiliated with GTCR ...
Negative
Reuters
29 days ago
The U.S. Federal Trade Commission sued on Thursday to block medical device coatings maker Surmodics' acquisition by private equity firm GTCR, with the regulatory agency alleging the deal was anticompetitive.
More Surmodics Inc News

Company Profile

SurModics, Inc. engages in the provision of medical device and in vitro diagnostic technologies to the healthcare industry. It operates through the Medical Device and In Vitro Diagnostics segments. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment consists of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Head office United States
CEO Gary Maharaj
Employees 389
Founded 1979
Website www.surmodics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today